Bavarian Nordic focuses on the research, development and manufacture of vaccines to prevent infectious diseases, including biological threats to national security such as smallpox, Ebola and more.
The company utilizes its patented MVA-BN® technology platform to develop a broad infectious disease vaccine pipeline. The lead program is a non-replicating smallpox vaccine based on MVA-BN, licensed in the European Union under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. The vaccine is being delivered to the U.S. Strategic National Stockpile for emergency use and the company is completing the Phase 3 clinical studies required to license the vaccine in the U.S.
To date, Bavarian Nordic has secured research and supply contracts for its biodefense programs totaling over $1 billion dollars.